Roivant Sciences had its Relative Strength (RS) Rating upgraded from 67 to 72 Monday — a welcome improvement, but still short of the 80 or better score you prefer to see.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating of at least 80 in the early stages of their moves. See if Roivant Sciences can continue to rebound and clear that threshold.
Roivant Sciences broke out earlier, but has fallen back below the prior 13.05 entry from a consolidation. If a stock you're tracking clears a buy point then declines 7% or more below the original entry price, it's considered a failed base. Wait for the stock to set up and breakout from a new base and buy point. Also understand that the most recent consolidation is a later-stage base, which makes it riskier to establish a new position or add shares to an existing one.
Roivant Sciences posted 0% EPS growth in its most recent report. Sales increased -73%.
The company holds the No. 269 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
